In Brief This Week: IntelligentMDx; Techne; Qiagen; Horizon Discovery; Penn Genome Frontiers Institute | GenomeWeb

NEW YORK (GenomeWeb News) – IntelligentMDx has received the CE Mark for its herpes simplex virus molecular test. The MDx HSV-1/2 runs on the Abbott m2000 platform and detects HSV viral DNA and differentiates HSV-1 and HSV-2 in male and female genital or oral lesions and cerebral spinal fluid.


Investment bank William Blair & Co. has initiated coverage of research reagents provider Techne with a Market Perform rating.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

A Karmagenes researcher has lost his position after reportedly admitting to data fabrication, according to Retraction Watch.

Two neuroscientists write in Nature News that solving the "reproducibility crisis" in science may require changing the requirements for publication.